Update in HIV-associated lymphoma

Current Opinion in Oncology

Volumn 16, Issue 5, 2004, Pages 450-454

  Noy, Ariela ^a,b,c  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

HIV; Hodgkin disease; Non Hodgkin lymphoma; Plasmablastic lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; CELL ADHESION MOLECULE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 10; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ANEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; THROMBOCYTOPENIA; VIRUS REPLICATION;

HUMANS; LYMPHOMA, AIDS-RELATED;

EID: 4344704523     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200409000-00007     Document Type: Review

References (37)

1. Sparano JA: Human immunodeficiency virus associated lymphoma. Curr Opin Oncol 2003, 15:372-378.
2. Thirlwell C, Sarker D, Stebbing J, Bower M: Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 2003, 4:86-92. Thorough review.
3. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003, 17:785-820. Extensive review of pathogenesis.
4. Breen EC, Boscardin WJ, Detels R, et al.: Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003, 109:119-129. Provocative data from a prospective database that may give insights into pathogenesis and patients at risk for the development of NHL.
5. Moses AV, Williams SE, Strussenberg JG, et al.: HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat Med 1997, 3:1242-1249.
6. Henderson WW, Ruhl R, Lewis P, et al.: Human Immunodeficiency Virus (HIV) type 1 Vpu induces the expression of CD40 in endothelial cells and regulates HIV-induced adhesion of E-lymphoma cells. J Virol 2004, 78:4408-4420. Insights into the extra-nodal propensity of HIV-associated NHL.
7. Little RF, Pittaluga S, Grant N, et al.: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003, 101:4653-4659. Infusional and dose-adjusted approach with additional insights into the pathobiology of HIV-associated NHL in the HAART era.
8. Giancola ML, Uccella I, Alba L, et al.: HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy. AIDS Res Hum Retroviruses 2003, 19:1091-1095.
9. Hoffmann C, Wolf E, Fatkenheuer G, et al.: Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003, 17:1521-1529. Further support that the control of HIV is important in those with NHL.
10. Simonelli C, Zanussi S, Cinelli R, et al.: Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy. Scand J Infect Dis Suppl 2003, 35(suppl 106):49-53. Further support that the control of HIV is important in those with NHL.
11. Sparano JA, Lee S, Chen MG, et al.: Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004, 22:1491-1500. Infusional therapy in the pre- and post-HAART era.
12. Costello RT, Zerazhi H, Charbonnier A, et al.: Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer 2004, 100:667-676. Feasibility of intensive chemotherapy in the HAART era.
13. Kaplan LD, Lee J, Scadden DT: No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkins lymphoma: Updated data from AIDS Malignancies Consortium Study 010. Proceedings of the American Society of Hematology. San Diego: 2003.
14. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
15. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-celi lymphoma (DLBCL). Blood 2003, 101:4279-4284.
16. Cortes J, Thomas D, Rios A, et al.: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002, 94:1492-1499.
17. Wang ES, Straus DJ, Teruya-Feldstein J, et al.: Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003, 98:1196-1205. Feasibility of short-term aggressive therapy for HIV-associated Burkitt's suggesting that outcome may be equivalent to the HIV-negative population. Treatment may be particularly efficacious in patients with either CNS or bone marrow involvement.
18. Astrow AB, Tarabay G, Salerno VE, et al.: Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy. Hematol Oncol 2003, 21:131-140. Support for intensive approach to HIV+ Burkitt's.
19. Oriol A, Ribera JM, Esteve J, et al.: Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003; 88:445-453. Further evidence that patients with aggressive histologies can be treated with aggressive chemotherapy programs despite HIV.
20. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al.: Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997, 89:1413-1420.
21. Porter SR, Diz Dios P, Kumar N, et al.: Oral plasmablastic lymphoma in previously undiagnosed HIV disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 87:730-734.
22. Lin Y, Rodrigues GD, Turner JF, Vasef MA: Plasmablastic lymphoma of the lung: report of a unique case and review of the literature. Arch Pathol Lab Med 2001, 125:282-285.
23. Borrero JJ, Pujol E, Perez S, et al.: Plasmablastic lymphoma of the oral cavity and jaws. AIDS 2002, 16:1979-1980.
24. Nguyen DD, Loo BW Jr, Tillman G, et al.: Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report. Ann Hematol 2003, 82:521-525.
25. Brown RS, Campbell C, Lishman SC, et al.: Plasmablastic lymphoma: a new subcategory of human immunodeficiency virus-related non-Hodgkin's lymphoma. Clin Oncol (R Coll Radiol) 1998, 10:327-329.
26. Pruneri G, Graziadei G, Ermellino L, et al.: Plasmablastic lymphoma of the stomach. A case report. Haematologica 1998, 83:87-89.
27. Carbone A, Gaidano G, Gloghini A, et al.: AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999, 108:95-99.
28. Chetty R, Hlatswayo N, Muc R, et al.: Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. Histopathology 2003, 42:605-609. A small case series showing an expanding spectrum for plasmablastic lymphoma beyond the oral cavity and jaw.
29. Teruya-Feldstein J, Chiao E, Filippa DA, et al.: CD20 negative large cell lymphoma with plasmablastic features: A clinically heterogenous spectrum in both HIV positive and negative patients. Annals of Oncology (in press).
30. Simonelli C, Spina M, Cinelli R, et al.: Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003, 21:3948-3954. A case series of PEL reporting clinical features and outcomes.
31. Klein U, Gloghini A, Gaidano G, et al.: Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003, 101:4115-4121. Molecular data demonstrating that PEL is a unique variant of HIV-associated NHL.
32. Skiest DJ, Crosby C: Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003, 17:1787-1793. Small series showing that HAART not only influences incidence of CNS NHL, but outcomes as well.
33. Raez L, Cabral L, Cai JP, et al.: Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999, 15:713-719.
34. Cingolani A, Gastaldi R, Fassone L, et al.: Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000, 18:3325-3330.
35. Sarker D, Thirlwell C, Nelson M, et al.: Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003, 17:861-865.
36. Krishnan A, Molina A, Zaia J, et al.: Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001, 98:3857-3859.
37. Re A, Cattaneo C, Michieli M, et al.: High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003, 21:4423-4427. Safety and efficacy of HDT and PBSCT in those with relapsed and primary refractory lymphoma and concomitant HIV infection.